BR112016011999A2 - Derivados de amida para agonista de gpr119 - Google Patents

Derivados de amida para agonista de gpr119

Info

Publication number
BR112016011999A2
BR112016011999A2 BR112016011999A BR112016011999A BR112016011999A2 BR 112016011999 A2 BR112016011999 A2 BR 112016011999A2 BR 112016011999 A BR112016011999 A BR 112016011999A BR 112016011999 A BR112016011999 A BR 112016011999A BR 112016011999 A2 BR112016011999 A2 BR 112016011999A2
Authority
BR
Brazil
Prior art keywords
amide derivatives
gpr119 agonist
innovative
compound
present
Prior art date
Application number
BR112016011999A
Other languages
English (en)
Inventor
Kim Yuntae
Lee Changsik
Choi Daekyu
Ko Moosung
Han Younghue
Kim Soyoung
Min Jaeki
Kim Dohoon
Original Assignee
Chong Kun Dang Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chong Kun Dang Pharmaceutical Corp filed Critical Chong Kun Dang Pharmaceutical Corp
Publication of BR112016011999A2 publication Critical patent/BR112016011999A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

DERIVADOS DE AMIDA PARA AGONISTA DE GPR119. A presente invenção refere-se a derivados de amida inovadores, estereoisômeros dos mesmos ou sais farmaceuticamente aceitáveis dos mesmos; a métodos para preparação do composto; e a composições farmacêuticas que compreendem o composto. Os derivados de amida inovadores, de acordo com a presente invenção, tendo um efeito como agonista de GPR119 podem ser usados para o tratamento de distúrbios metabólicos, incluindo diabetes mellitus (especialmente do tipo II) e distúrbios relacionados.
BR112016011999A 2013-11-26 2014-11-25 Derivados de amida para agonista de gpr119 BR112016011999A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20130144601 2013-11-26
PCT/KR2014/011356 WO2015080446A1 (en) 2013-11-26 2014-11-25 Amide derivatives for gpr119 agonist

Publications (1)

Publication Number Publication Date
BR112016011999A2 true BR112016011999A2 (pt) 2017-08-08

Family

ID=53199342

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016011999A BR112016011999A2 (pt) 2013-11-26 2014-11-25 Derivados de amida para agonista de gpr119

Country Status (20)

Country Link
US (1) US9776987B2 (pt)
EP (1) EP3074384B1 (pt)
JP (1) JP6182269B2 (pt)
KR (1) KR101700906B1 (pt)
CN (2) CN105873916B (pt)
AU (1) AU2014354488B2 (pt)
BR (1) BR112016011999A2 (pt)
CA (1) CA2930850C (pt)
DK (1) DK3074384T3 (pt)
ES (1) ES2731823T3 (pt)
HR (1) HRP20191246T1 (pt)
HU (1) HUE045926T2 (pt)
MX (1) MX366297B (pt)
NZ (1) NZ720304A (pt)
PH (1) PH12016500980B1 (pt)
PL (1) PL3074384T3 (pt)
PT (1) PT3074384T (pt)
RU (1) RU2642429C2 (pt)
TR (1) TR201908098T4 (pt)
WO (1) WO2015080446A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4153589A4 (en) 2020-05-19 2024-06-12 Kallyope, Inc. AMPK ACTIVATORS
WO2021263039A1 (en) 2020-06-26 2021-12-30 Kallyope, Inc. Ampk activators

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5109002A (en) 1989-09-08 1992-04-28 Du Pont Merck Pharmaceutical Company Antipsychotic 1-cycloalkylpiperidines
EP1167326B2 (en) 2000-06-26 2007-11-14 Saudi Basic Industries Corporation Dimerization of isobutene
JP5265838B2 (ja) 2000-07-13 2013-08-14 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング キラルな化合物ｉ
WO2002034739A1 (en) 2000-10-20 2002-05-02 Merck Patent Gmbh Chiral binaphthol derivatives
DE102004037515A1 (de) 2003-08-22 2005-03-17 Merck Patent Gmbh Verfahren zur Herstellung von Aldehyden
US20080103123A1 (en) 2006-08-30 2008-05-01 Biovitrum New compounds
US8101634B2 (en) * 2006-12-06 2012-01-24 Glaxosmithkline Llc Bicyclic compounds and use as antidiabetics
RS52065B (en) 2007-01-04 2012-06-30 Prosidion Ltd PIPERIDINSKI GPCR AGONIST
AU2008279447A1 (en) 2007-07-19 2009-01-29 Metabolex, Inc. N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the RUP3 or GPR119 receptor for the treatment of diabetes and metabolic disorders
ES2499018T3 (es) 2007-09-20 2014-09-26 Irm Llc Compuestos y composiciones como moduladores de la actividad de GPR119
WO2009106565A1 (en) 2008-02-27 2009-09-03 Biovitrum Ab (Publ) Agonists of gpr119
WO2009106561A1 (en) * 2008-02-27 2009-09-03 Biovitrum Ab (Publ) Pyrazine compounds for treating gpr119 related disorders
ES2429129T3 (es) 2008-07-11 2013-11-13 Irm Llc 4-Fenoximetilpiperidinas como moduladores de la actividad de GPR119
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
AR077642A1 (es) 2009-07-09 2011-09-14 Arena Pharm Inc Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
AR077638A1 (es) * 2009-07-15 2011-09-14 Lilly Co Eli Compuesto de (metanosulfonil -piperidin )-( alcoxi-aril) -tetrahidro- piridina , composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para el tratamiento de diabetes u obesidad
EP2556056A1 (en) * 2010-04-06 2013-02-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2011145718A1 (ja) * 2010-05-21 2011-11-24 田辺三菱製薬株式会社 新規ピロロ［２，３－ｄ］ピリミジン化合物
TW201202230A (en) 2010-05-24 2012-01-16 Mitsubishi Tanabe Pharma Corp Novel quinazoline compound
CN102432598A (zh) * 2010-09-29 2012-05-02 江苏恒瑞医药股份有限公司 三环化合物、其制备方法及其在医药上的应用
CA2818050A1 (en) * 2010-11-26 2012-05-31 Lupin Limited Bicyclic gpr119 modulators
WO2012077655A1 (ja) 2010-12-07 2012-06-14 塩野義製薬株式会社 Ｇｐｒ１１９アゴニスト活性を有するスピロ誘導体
JP2014159376A (ja) * 2011-06-17 2014-09-04 Taisho Pharmaceutical Co Ltd アザスピロアルカン化合物
CA2867114C (en) * 2012-06-12 2016-02-23 Chong Kun Dang Pharmaceutical Corp. Piperidine derivatives for gpr119 agonist
WO2013187464A1 (ja) * 2012-06-13 2013-12-19 日産自動車株式会社 車両の駆動力制御装置

Also Published As

Publication number Publication date
CA2930850A1 (en) 2015-06-04
PT3074384T (pt) 2019-07-10
CN105873916A (zh) 2016-08-17
JP2016538296A (ja) 2016-12-08
US9776987B2 (en) 2017-10-03
PH12016500980A1 (en) 2016-06-20
RU2016125492A (ru) 2018-01-09
EP3074384B1 (en) 2019-05-22
CN105873916B (zh) 2019-08-27
KR20150060573A (ko) 2015-06-03
AU2014354488B2 (en) 2017-08-24
NZ720304A (en) 2017-08-25
CA2930850C (en) 2017-05-16
WO2015080446A1 (en) 2015-06-04
MX2016006904A (es) 2016-10-28
MX366297B (es) 2019-07-04
RU2642429C2 (ru) 2018-01-25
PH12016500980B1 (en) 2016-06-20
CN110028494A (zh) 2019-07-19
KR101700906B1 (ko) 2017-01-31
HUE045926T2 (hu) 2020-01-28
TR201908098T4 (tr) 2019-06-21
AU2014354488A1 (en) 2016-06-09
DK3074384T3 (da) 2019-07-15
ES2731823T3 (es) 2019-11-19
EP3074384A4 (en) 2017-04-19
PL3074384T3 (pl) 2019-09-30
HRP20191246T1 (hr) 2019-12-27
JP6182269B2 (ja) 2017-08-16
US20170129875A1 (en) 2017-05-11
EP3074384A1 (en) 2016-10-05

Similar Documents

Publication Publication Date Title
BR112014031091A2 (pt) Derivados de piperidina para agonista de gpr119
BR112015022972A2 (pt) composição farmacêutica de cloridrato de s-cetamina
BR112015003188A2 (pt) Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BR112015031903A2 (pt) composto, sal farmaceuticamente aceitável do composto, composição farmacêutica e utilização de um composto
BR112016016844A2 (pt) Compostos heterocíclicos
BR112015022191A2 (pt) compostos heteroarila, seu uso e composição que os compreende
EA201491060A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
BR112016010383A2 (pt) compostos de pyy seletivos e usos dos mesmos
BR112015024530A2 (pt) composto, métodos para tratamentos de distúrbios e de doenças e para profilaxia de distúrbios, composição farmacêutica, e, uso de um composto
CR20150480A (es) Composición farmacéutica de clorhidrato de s-cetamina
BR112019003932A2 (pt) composto, composição farmacêutica, combinação, método de tratamento de uma doença ou desordem e uso do composto
BR112016011755A2 (pt) derivado de ureia ou sal farmacologicamente aceitável do mesmo
BR112018070123A2 (pt) oxiesterós e métodos de uso dos mesmos
EA201690888A1 (ru) Новые гетероциклические соединения
BR112016030733A2 (pt) Derivados de indano e indolina e uso dos mesmos como ativadores de guanilato ciclase solúveis
NZ720328A (en) Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease
BR112015030399B8 (pt) Derivados heterocíclicos, uso dos referidos derivados e composição farmacêutica para a prevenção ou tratamento de doenças associadas com a ativação da proteína stat3
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
BR112015022758A2 (pt) derivados de pirrolidina, composições farmacêuticas contendo os mesmos e seu uso em terapia
BR112017026272A2 (pt) ?composto, composição farmacêutica, método para o tratamento de uma desordem relacionada a receptor m1 muscarínico e uso do composto?
BR112016026552A8 (pt) derivados de carboxamida, seus usos, composição farmacêutica, e combinação
EA201890684A1 (ru) Производные фториндола в качестве положительных аллостерических модуляторов мускаринового рецептора m1
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios
BR112018073419A2 (pt) combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica
BR112016013974A2 (pt) Composto, composição farmacêutica, uso da composição farmacêutica e uso do composto

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time